BA/BE Studies for Early Termination [Two-Stage / GS Designs]

posted by balakotu – India, 2015-09-22 15:05 (3916 d 14:12 ago) – Posting: # 15441
Views: 8,296

Dear all,

We are planning to conduct one "Replicate 4-period" bio-equivalence study with 70 subjects.

After completion of clinical phase we will analyze only 40 subjects.

If 40 subject’s data is shown bio-equivalent then we will stop the analysis of remaining 30 subjects. If the data is predictable then we will analyze remaining 30 subjects.

Please clarify whether this approach/design is acceptable to regulatory are not.

Regards

Kotu


Edit: Category changed. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,571 registered users;
117 visitors (0 registered, 117 guests [including 30 identified bots]).
Forum time: 05:17 CEST (Europe/Vienna)

To propose that poor design can be corrected by subtle analysis techniques
is contrary to good scientific thinking.    Stuart J. Pocock

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5